Board of Directors
Meet the members who guide and bring long-term vision to Après-demain SA
Presidence & Direction
Thierry MauvernayPresident, Delegate of the Board, Après-demain SA
President, Delegate of the Board, Après-demain SA
With the aspiration of bringing curative drug therapies and visionary healthcare solutions to patients worldwide, Mr. Mauvernay is President of Après-demain SA, the parent company of Debiopharm, a Swiss, privately owned, biopharmaceutical company founded by his father over 40 years ago. Debiopharm, with 15 ongoing drug research programs, has developed two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd Head & Neck Cancer drug currently in phase III development with an international partner. Après-demain SA invests in a variety of industries including companies impacting sustainable energy, education, food, services to individuals with real estate, via 30+ direct investments in companies as well as LP investments in more than 100 funds globally. In addition, Mr. Mauvernay is also Chairman of the investment committee of Debiopharm Innovation Fund, backed by his experience as an entrepreneur in the international cosmetics industry before joining his family’s drug development business and asset diversification activities. His educational background includes a Master of Science in Economics and Marketing along with an MBA from the 'Institut d'Administration des Entreprises’.
Valérie CalvayracSenior Vice President, Asset Management
Senior Vice President, Asset Management
Ms Calvayrac graduated from the University of Paris (Panthéon-Assas), where she obtained a "Diplôme d'Etudes Supérieures Spécialisées" in Business Law and Tax in 1988 (DESS, currently called "Master II Degree"). She then started a career in the banking sector during which she acquired a broad experience in various positions at Le Crédit Lyonnais (Crédit Agricole Group) in Marketing, Corporate Financing, Retail Banking and Human Resources, before becoming Director of the Financing Department for France, in charge of the Financing for Small Enterprises and of the Real Estate Financing for individuals. In April 2008 she joined the Asset Management team of Après-demain SA as General Secretary and was appointed Director in 2010. Since 2020, she has served as the Senior Vice President of the Asset Management team of Après-demain SA. She sits on the boards of various companies of Après-demain SA, including some portfolio investment companies.
Bertrand DucreySenior Vice President, Life Science
Senior Vice President, Life Science
Dr. Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switzerland in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. In the same he joined Debiopharm Research & Manufacturing SA as Pharmaceutical Project Manager. He then spent two years at Debiopharm International SA as Innovative Formulation Manager. In 2004, he returned to Debiopharm Research & Manufacturing to head the company as Chief Executive Officer until 2011. Since 2012, Dr. Ducrey heads Debiopharm International SA as CEO. In 2020, he became Senior Vice-President of the Life Science Division of Après-demain SA.